Time-resolved fluorescence comprehensive detection kit of uterine cancer and application thereof

A time-resolved fluorescence and comprehensive detection technology, which is applied in the direction of fluorescence/phosphorescence, measuring devices, and analytical materials, can solve the problems of large differences in judgment results, errors in detection results, and numerous detection steps, achieving fewer steps, shorter time, The effect of improving specificity and sensitivity

Inactive Publication Date: 2013-05-29
河南生生医疗器械有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Conventional laboratories or medical units usually use a single kit for the detection of these four indicators, that is, one kit for the detection of one tumor marker. The disadvantages of this method are: 1. There are many detection steps, which are time-consuming and laborious; 2. , At present, the four markers are detected by four single-index kits, and then comprehensively judged. Due to

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Time-resolved fluorescence comprehensive detection kit of uterine cancer and application thereof
  • Time-resolved fluorescence comprehensive detection kit of uterine cancer and application thereof
  • Time-resolved fluorescence comprehensive detection kit of uterine cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The time-resolved fluorescence method comprehensive detection kit for uterine cancer provided in this example includes: anti-SCC antibody H00006317-M01, anti-CA125 antibody M32112M, anti-CEA antibody MAM02-008, anti-β-HCG antibody 10R-75154 Antibody-coated microplates composed of a mixture of monoclonal antibodies; with Eu 3+ Labeled H00025816-A01 antibody (anti-SCC antibody), with Tb 3+ Labeled M86306M antibody (anti-CA125 antibody), with Sm 3+ Labeled MAM02-881 antibody (anti-CEA antibody), with Dy 3+ Labeled 10R-7751 antibody (anti-β-HCG antibody) mixed antibody composed of four monoclonal antibodies; analysis buffer; shared fluorescence enhancer; washing solution; four standard mixtures of SCC, CA125, CEA, and β-HCG Consists of quality controls. The kit also includes negative controls, positive controls, substrates and other related reagents.

[0034] In the kit provided in this example, anti-SCC antibodies H00006317-M01 and H00025816-A01 were purchased from Abn...

Embodiment 2

[0047] The application of the kit provided in Example 1 of the present invention in the comprehensive detection of uterine cancer tumor markers SCC, CA125, CEA, and β-HCG, that is, the kit provided in Example 1 of the present invention is used to comprehensively detect uterine cancer tumor markers at the same time SCC, CA125, CEA, β-HCG time-resolved fluorescent immunoassay method, the reaction principle is as follows figure 1 As shown, the double-antibody sandwich method is used, including the following steps:

[0048] (1) Dilute the four protein standard mixtures of SCC, CA125, CEA, and β-HCG with the analysis buffer, that is, the quality control product, and make a series of concentration gradients containing the four protein standards of SCC, CA125, CEA, and β-HCG The mixed solution of the product;

[0049] (2) Take 100 μl human serum of the sample to be tested and the mixed solution of four protein standards prepared in step (1), and add the mixed antibody package compos...

Embodiment 3

[0051] The numerical values ​​of SCC, CA125, CEA, β-HCG four indexes that test kit of the present invention obtains with 35 serum samples and test SCC with the single indicator kit of Abbott Company respectively with the same 35 serum samples, Roche Company's The data obtained by testing CA125 with a single-index kit, testing CEA with a single-index kit from Abbott, and testing β-HCG with a single-index kit from Siemens were respectively subjected to regression correlation analysis. figure 2 , 3 , 4, 5, as can be seen from the accompanying drawings, each index data obtained by the test kit of the present invention has a good correlation with the data obtained by the test of the single index kit respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biological and medical detection, and particularly relates to a time-resolved fluorescence immunoassay kit for comprehensively detecting uterine cancer tumor markers SCC (Squamous Cell Carcinoma), CEA (Carcinoma Embryonic Antigen), CA125 (Carcinoma Antigen 125), and beta-HCG (Human Chorionic Gonadotropin) simultaneously in a same reaction system, and further relates to application of the kit in comprehensive detection of the uterine cancer tumor markers SCC, CEA, CA125, and beta-HCG simultaneously. The kit comprises a first monoclonal antibody mixed antibody coated microplate for respectively resisting SCC, CEA, CA125, and beta-HCG, a second monoclonal antibody mixed antibody of Eu<3+> labeled anti-SCC, Sm<3+> labeled anti-CEA, Tb<3+> labeled anti-CA125 and Dy<3+> labeled anti-beta-HCG, an analytical buffer solution, a common fluorescence reinforcing agent, a washing liquid and a quality control product. The kit related by the invention can be used in clinical auxiliary diagnosis, curative effect observation, and prognosis judgment of the uterine cancer, has a great significance on the treatment and prevention of the uterine cancer, and can be used for detecting the four tumor markers simultaneously, thereby simplifying detection steps, and improving the specificity and the sensitivity of the comprehensive analysis of detection data.

Description

technical field [0001] The invention relates to the technical field of biological and medical detection, in particular to a time-resolved fluorescent immunoassay kit for simultaneously comprehensively detecting uterine cancer tumor markers SCC, CA125, CEA, and β-HCG in the same reaction system, and also relates to the Application of the kit in the comprehensive detection of uterine cancer tumor markers SCC, CA125, CEA, and β-HCG. Background technique [0002] Uterine cancer is a general term for a series of malignant tumors that occur in the uterus. The most common intrauterine cancers are endometrial cancer and cervical cancer. About 131,500 new cases of uterine cancer are discovered every year in my country, and the early detection and cure rate is relatively high. Therefore, early and more accurate diagnosis of uterine cancer is still the key to the treatment of this disease. [0003] At present, the commonly used detection indicators for diagnosing uterine cancer inclu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/577G01N33/531G01N33/533G01N21/64
Inventor 王嘎程自卿
Owner 河南生生医疗器械有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap